Frailty and sarcopenia: definitions and outcome parameters

Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, Sieber C, Kaufman JM, Van Kan GA, Boonen S, Adachi J, Mitlak B, Tsouderos Y, Rolland Y, Reginster JYL (2012)

Publication Status: Published

Publication Type: Journal article

Publication year: 2012

Journal

Osteoporosis international Springer Verlag (Germany)

Publisher: SPRINGER LONDON LTD

Book Volume: 23

Pages Range: 1839-1848

Journal Issue: 7

DOI: 10.1007/s00198-012-1913-1

Abstract

An operational definition of musculoskeletal decline in older people is needed to allow development of interventions for prevention or treatment, as was developed for the treatment of osteoporosis. Frailty and sarcopenia are linked, but distinct, correlates of musculoskeletal aging that have many causes, including age-related changes in body composition, inflammation, and hormonal imbalance. With the emergence of a number of exciting candidate therapies to retard the loss of muscle mass with aging, the derivation of a consensual definition of sarcopenia and physical frailty becomes an urgent priority. Although several consensual definitions have been proposed, these require clinical validation. An operational definition, which might provide a threshold for treatment/trial inclusion, should incorporate a loss of muscle mass as well as evidence of a decrease in muscle strength and/or physical activity. Evidence is required for a link between improvements in the measures of muscle strength and/or physical activity and clinical outcomes to allow development of interventions to improve clinical outcomes in frail older patients.

Authors with CRIS profile

Cornel Sieber Lehrstuhl für Innere Medizin (Geriatrie)

Involved external institutions

University Hospital Ghent BE Belgium (BE) University of Southampton GB United Kingdom (GB) Geneva University Hospitals / Hôpitaux universitaires de Genève (HUG) CH Switzerland (CH) University of Sheffield GB United Kingdom (GB) GlaxoSmithKline plc. (GSK) GB United Kingdom (GB) Amgen Ltd GB United Kingdom (GB) University of Liège (ULg) / Université de Liège BE Belgium (BE) Laboratoires Servier FR France (FR) Eli Lilly and Company US United States (USA) (US) McMaster University CA Canada (CA) Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven BE Belgium (BE) Centre Hospitalier Universitaire (CHU) de Toulouse FR France (FR)

How to cite

APA:

Cooper, C., Dere, W., Evans, W., Kanis, J.A., Rizzoli, R., Sayer, A.A.,... Reginster, J.-Y.L. (2012). Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis international, 23(7), 1839-1848. https://dx.doi.org/10.1007/s00198-012-1913-1

MLA:

Cooper, Cyrus, et al. "Frailty and sarcopenia: definitions and outcome parameters." Osteoporosis international 23.7 (2012): 1839-1848.

BibTeX: Download